Schwab Co-Chairman Sells $18M as Options Calm and Shorts Retreat

SCHW enters November with a notable shift in tone: the defensive options positioning that dominated last week's note has unwound, shorts continue their steady exit, and the most newsworthy development is now coming from the insider register rather than the derivatives market.

The clearest signal this week is from Charles Schwab himself. The co-chairman sold 136,400 shares on October 29 at $89.50 and a further 66,750 shares on October 28 at $88.36, bringing the combined value of those two trades to roughly $18.1 million. Neither sale was made under a 10b5-1 pre-arranged trading plan, which makes them discretionary transactions rather than scheduled compensation mechanics. Net insider activity over the past 90 days amounts to a disposal of 856,735 shares worth approximately $90.3 million, almost entirely driven by the co-chairman's sales. With the stock having fallen 7.7% over the past month to $89.28, the timing is conspicuous: Schwab is selling into weakness, not strength.

Options positioning has pulled back from last week's defensive extreme. The put/call ratio has eased to 0.97 from the 1.01 reading on October 27 that was flagged in the previous note as nearly three standard deviations above its 20-day average. The ratio is now closer to its 20-day mean of 0.94, with a z-score of just 0.75. That is a meaningful de-escalation: the investors who had rotated into downside protection following the Q3 results appear to have trimmed those hedges. The PCR's 52-week range runs from 0.74 to 1.46, so current levels are neither alarmed nor complacent.

Short interest continues to unwind and is no longer a primary driver of the story. At less than 1% of the free float and down roughly 4.5% on the week, it has fallen around 15% from its late-September levels above 21 million shares. Borrow cost has collapsed to 0.16%, down 74% on the week, after briefly spiking above 0.61% in late October. Availability remains effectively unlimited. The lending market sends no distress signal whatsoever.

The Street's view is cautious but not uniformly negative. Morgan Stanley maintained its Overweight rating on October 21 while cutting its target from $141 to $132, the most bullish target in the recent round of revisions. JPMorgan kept Overweight with a $147 target on October 16, also trimmed from $150. Those two positive ratings sit alongside Evercore ISI's In-Line at $98, cut again on October 28 from $104, and BMO's Market Perform at $97. The consensus target has settled at around $117, implying roughly 31% upside from the current price. The bull case centres on Schwab's record Q3 core net new assets of $190.4 billion, 29% adjusted EPS growth, and AI-driven operating leverage. Bears point to management's Q4 NIM guidance of 3.15% to 3.20%, which implies only modest expansion, and to the balance sheet's ongoing reliance on wholesale funding as a potential margin drag. Factor scores are quietly constructive: the ORTEX short score rank sits at the 73rd percentile and days-to-cover rank at the 74th, while EPS momentum over 30 and 90 days both register above the 60th percentile.

On the alt data front, FDIC call reports show Schwab's insured bank net loans and leases have risen for nine consecutive quarters to $67.2 billion, and net income at the bank level has risen for seven straight quarters to $1.0 billion as of the April 2026 period. These datasets have not yet been tested as leading indicators against Schwab's reported figures, so they serve as colour on the balance sheet trajectory rather than a signal for the next print. The next earnings event is scheduled for January 15, 2027, leaving 72 days for the current-quarter picture to develop further.

What to watch next: whether the co-chairman's discretionary selling continues at the same pace through November, and whether the options market reverts to the defensive posture seen a week ago or continues to reflect a more relaxed read on the stock going into year-end.